Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.50 |
| ▸ | TACR1 | P25103 | 4/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242591 | 0.91 | GPR119 (0.54) | GPR119PDE4BTACR1RORCMEN1 | |
| SCHEMBL2242454 | 0.91 | GPR119 (0.54) | GPR119PDE4BTACR1RORCMEN1 | |
| SCHEMBL2240929 | 0.91 | GPR119 (0.54) | GPR119PDE4BTACR1RORCMEN1 | |
| SCHEMBL2248421 | 0.91 | GPR119 (0.54) | GPR119PDE4BTACR1RORCMEN1 | |
| SCHEMBL3193293 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 | |
| SCHEMBL14403275 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 | |
| SCHEMBL3194550 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 | |
| SCHEMBL1751263 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 | |
| SCHEMBL3193282 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 | |
| SCHEMBL1970240 | 0.88 | RORC (0.56) | GPR119PDE4BTACR1RORCUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | GPR119 105/4885PDE4B 1291/4885TACR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.